These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 6346866)

  • 21. Renal transplantation vs hemodialysis: cost-effectiveness analysis.
    Perović S; Janković S
    Vojnosanit Pregl; 2009 Aug; 66(8):639-44. PubMed ID: 19780419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost of starting and maintaining a large home hemodialysis program.
    Komenda P; Copland M; Makwana J; Djurdjev O; Sood MM; Levin A
    Kidney Int; 2010 Jun; 77(11):1039-45. PubMed ID: 20375983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of hemodialysis: implications for technology assessment in Greece.
    Kaitelidou D; Ziroyanis PN; Maniadakis N; Liaropoulos LL
    Int J Technol Assess Health Care; 2005; 21(1):40-6. PubMed ID: 15736513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes: changing the fate of diabetics in the dialysis unit.
    Broumand B
    Blood Purif; 2007; 25(1):39-47. PubMed ID: 17170536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End-stage renal disease in India and Pakistan: burden of disease and management issues.
    Sakhuja V; Sud K
    Kidney Int Suppl; 2003 Feb; (83):S115-8. PubMed ID: 12864888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of High Dose Hemodialysis in Comparison to Conventional In-Center Hemodialysis in the Netherlands.
    Beby AT; Cornelis T; Zinck R; Liu FX
    Adv Ther; 2016 Nov; 33(11):2032-2048. PubMed ID: 27664108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. End-stage renal care in developing countries: the India experience.
    Jha V
    Ren Fail; 2004 May; 26(3):201-8. PubMed ID: 15354966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment bias in the management of end-stage renal disease.
    Smith MD; Hong BA; Michelman JE; Robson AM
    Am J Kidney Dis; 1983 Jul; 3(1):21-6. PubMed ID: 6346863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
    Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
    G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost analysis of dialysis modalities in Italy.
    Tediosi F; Bertolini G; Parazzini F; Mecca G; Garattini L
    Health Serv Manage Res; 2001 Feb; 14(1):9-17. PubMed ID: 11246787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost calculations during "dire straits": a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece.
    Naoum P; Topkaroglou I; Kitsonis D; Skroumpelos A; Athanasakis K; Iatrou C; Boletis J; Kyriopoulos J
    Int J Artif Organs; 2016 Feb; 39(2):87-9. PubMed ID: 26953901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Self dialysis: a new method of treatment for end-stage renal disease].
    Fournier G; Gaillard JL; Matha N; Man NK
    Nephrologie; 1984; 5(3):115-8. PubMed ID: 6493429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
    Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
    Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Home hemodialysis: patient outcomes during a 24-year period of time from 1970 through 1993.
    Mailloux LU; Kapikian N; Napolitano B; Mossey RT; Bellucci AG; Wilkes BM; Vernace MA; Miller IJ
    Adv Ren Replace Ther; 1996 Apr; 3(2):112-9. PubMed ID: 8814916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry.
    McDonald SP; Russ GR; Kerr PG; Collins JF;
    Am J Kidney Dis; 2002 Dec; 40(6):1122-31. PubMed ID: 12460029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting treatment costs and life expectancy for end-stage renal disease.
    Stange PV; Sumner AT
    N Engl J Med; 1978 Feb; 298(7):372-8. PubMed ID: 340947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.